An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.

<h4>Background</h4>Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This community study was designed to compare the safety and efficacy of MDA with IDA (ivermectin, diethylcarbamazine and albendazole) o...

Full description

Bibliographic Details
Main Authors: Purushothaman Jambulingam, Vijesh Sreedhar Kuttiatt, Kaliannagounder Krishnamoorthy, Swaminathan Subramanian, Adinarayanan Srividya, Hari Kishan K Raju, Manju Rahi, Roopali K Somani, Mallanna K Suryaprakash, Gangeshwar P Dwivedi, Gary J Weil
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-02-01
Series:PLoS Neglected Tropical Diseases
Online Access:https://doi.org/10.1371/journal.pntd.0009069

Internet

https://doi.org/10.1371/journal.pntd.0009069

Similar Items